Clarivate Epidemiology’s coverage of hepatitis c virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of HCV for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s HCV forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with HCV per year?
How will improvements in survival change the number of people living with HCV?
Of all people with HCV, how many in each country have been formally diagnosed?
Of all people diagnosed with HCV, how many in each country are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HCV over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts 49 HCV patient populations, including the following:
Total Prevalence of Hepatitis C Virus per 1,000 per Year Among People of All Ages in 2021 and 2031ttttttttttttttt
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Hepatitis C Virus Over the Next 10 Years
Analysis of Viremic Prevalent Cases of Hepatitis C Virus in 2021 by Genotype
Total Seroprevalent Cases
Total Incident Cases
Total Prevalent Viremic Cases
Prevalence of Hepatitis C Virus by Genotype
Liver Cirrhosis by Hepatitis C Virus Genotype
Diagnosed Prevalent Cases
Drug-Treated Prevalent Cases
Studies Included in the Analysis of Hepatitis C Virus
Studies Excluded From the Analysis of Hepatitis C Virus
Risk/Protective Factors for HCV
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.